Prof. Andrea Alimonti advises Peptone on clinical oncology and collaborates with the company on AR-NTD mechanism of action and disease biology. Director of the Institute of Oncology Research, he trained in medicine and oncology in Rome and completed cancer biology fellowships at Memorial Sloan Kettering and Harvard; his research examines senescence, immune responses, and treatment resistance in prostate cancer.
Scientific Advisor for Clinical Oncology